AstraZeneca Pharma India Ltd reported mixed financial results for Q1 FY27 (good revenue growth but a sharp decline in earnings). It reported a 32.1% year-on-year (YoY) decline in consolidated net profit to Rs 37.6 crore for Q1 FY27 (compared to Rs 56.4 crore in Q1 FY26).
Despite the poor bottom line performance, revenue from operations grew substantially in the quarter. The company's revenue went up 29.8% year-on-year to Rs 682.8 crore in the first quarter compared to Rs 526.3 crore in the first quarter of the previous year.
The revenue performance versus profit contrast highlights the pressure on the company’s operating profitability during the quarter.
EBITDA declines 40%
In terms of operations, AstraZeneca Pharma India reported a significant decline in earnings before interest, taxes, depreciation and amortisation (EBITDA). EBITDA fell 40% YoY to Rs 49 crore; it rose to Rs 81.7 crore in the previous year.
The EBITDA margin also fell sharply to 7.2% in Q1 FY27 from 15.5% in Q1 FY26. The large margin compression was one of the reasons behind the company’s profitability decline under the strong revenue growth.
The results highlight that although AstraZeneca Pharma India continued to see healthy demand in its key therapy areas, higher operating costs or changes in the revenue mix weighed on earnings at the operating level.
Oncology is still one of the largest growth drivers
AstraZeneca Pharma India said its quarterly performance was supported by continued momentum in its core therapy areas: Oncology, Biopharmaceuticals and Rare Diseases.
The Oncology business continues to be the company's largest contributor. Revenue from the segment increased 26% YoY to Rs 464.9 crore during the quarter.
The company’s Biopharmaceuticals business, consisting of CVRM, Respiratory & Immunology (R&I) and Vaccines & Immunology (V&I), also showed strong growth. The business in the segment grew 36% YoY to Rs 161.9 crore.
The Rare Diseases business saw the fastest percentage growth in percentage terms, with segment business growing 35 times in the quarter to Rs 14.4 crore. The segment is still small as compared to Oncology and Biopharmaceuticals, but its growth rate is still high compared to the growth rate of AstraZeneca's rare disease portfolio; it is contributing significantly in terms of percentage of the total company.
Portfolio expansion and strategic initiatives
AstraZeneca Pharma India pointed towards several strategic developments in the quarter. It had added to its portfolio and expanded scientific engagement with certain regulatory approvals and focused capability building activities.
The company also developed strategic partnerships to help earlier diagnosis and wider access to medicines.
These efforts could enable AstraZeneca to expand its presence in specialised therapy areas and, indeed, to grow the company in the long term when the demand for new treatments is more and more intense in India's healthcare market.
AstraZeneca Pharma share price
AstraZeneca Pharma India’s weak profitability performance appeared to weigh on investors’ sentiment for the day’s trading.
At 2:30 pm on August 10, 2026, AstraZeneca Pharma shares were down 1.18% to Rs 8,091.80 each on the BSE.
The stock's move is driven by investors weighing the company's strong revenue growth against the sharp contraction in EBITDA and net profit. An operating margin decline that could be significant for investors in the quarters to come is going to be one of the main concerns investors will have to watch out for.
Key takeaway for investors
AstraZeneca Pharma India’s Q1 FY27 performance is mixed. On the one hand, almost 30% revenue growth implies the company is seeing solid growth in its major therapy areas. Oncology and Biopharmaceuticals have continued to grow at a healthy rate, and Rare Diseases is on the rise from a smaller base.
But the 32.1% decline in net profit and 40% decline in EBITDA raised questions about the company’s profitability. The drop in EBITDA margin from 15.5% to 7.2% is especially significant and will be closely watched by investors.
In the longer term, the company’s ability to maintain revenue and operating margins could be crucial; future earnings will depend on this. More growth in Oncology, Biopharmaceuticals and Rare Diseases and new regulatory approvals and strategic alliances would also be expansion opportunities. But efficiency and profitability will be key in the near future.
Comments
Please to leave a comment on this article.